![]() |
« Back |
Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia
June 19, 2017 at 6:45 AM EDT
|
“This is a disappointing and unexpected result for the CASCADE trial.
Patient safety is our highest priority, and we will closely review the
data and evaluate next steps. AML is a devastating disease with a poor
prognosis in most patients, and there is a great need for therapeutics
against this disease. We thank the patients, caregivers and
investigators for their support of this trial,” said The phase 3 CASCADE clinical trial is a randomized, double-blind, placebo-controlled study evaluating vadastuximab talirine in combination with the hypomethylating agents (HMAs) azacitidine or decitabine compared to an HMA alone in older patients with newly diagnosed AML. Vadastuximab talirine is a novel investigational ADC targeted to CD33 utilizing Seattle Genetics’ proprietary ADC technology. CD33 is expressed on most AML and MDS blast cells.
About
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to Seattle Genetics’
future actions and plans with respect to its vadastuximab talirine
(SGN-CD33A) development program, Seattle Genetics’ expectations with
respect to the opportunities related to the remainder of its pipeline,
Seattle Genetics’ expectations for future ADCETRIS and enfortumab
vedotin clinical trial events and the timing thereof, and other
statements that are not historical facts. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a difference
include the possibility that the safety profile of vadastuximab talirine
may not support further development of the drug candidate or of adverse
regulatory action, and the possibility that
View source version on businesswire.com: http://www.businesswire.com/news/home/20170619005466/en/ Source:
Seattle Genetics, Inc. |